Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Advanced Thymoma and Thymic Carcinoma
NCT01621568Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in thymoma and thymic carcinoma (TC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started May 2012; status: completed.
02
Drugs
sunitinib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT01621568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621568.